- Home
- CISS vs GLMD Comparison
CISS vs GLMD Comparison
Compare CISS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- GLMD
- Stock Information
- Founded
- CISS 2022
- GLMD 2000
- Country
- CISS Greece
- GLMD Israel
- Employees
- CISS N/A
- GLMD N/A
- Industry
- CISS Marine Transportation
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- GLMD Health Care
- Exchange
- CISS Nasdaq
- GLMD Nasdaq
- Market Cap
- CISS 2.8M
- GLMD 3.0M
- IPO Year
- CISS N/A
- GLMD 2014
- Fundamental
- Price
- CISS $3.35
- GLMD $1.94
- Analyst Decision
- CISS
- GLMD Hold
- Analyst Count
- CISS 0
- GLMD 1
- Target Price
- CISS N/A
- GLMD N/A
- AVG Volume (30 Days)
- CISS 125.1K
- GLMD 414.8K
- Earning Date
- CISS 08-21-2025
- GLMD 08-27-2025
- Dividend Yield
- CISS N/A
- GLMD N/A
- EPS Growth
- CISS N/A
- GLMD N/A
- EPS
- CISS N/A
- GLMD N/A
- Revenue
- CISS $38,174,754.00
- GLMD N/A
- Revenue This Year
- CISS N/A
- GLMD N/A
- Revenue Next Year
- CISS N/A
- GLMD N/A
- P/E Ratio
- CISS N/A
- GLMD N/A
- Revenue Growth
- CISS N/A
- GLMD N/A
- 52 Week Low
- CISS $2.85
- GLMD $1.15
- 52 Week High
- CISS $23.25
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- CISS 44.02
- GLMD 63.61
- Support Level
- CISS $3.26
- GLMD $1.74
- Resistance Level
- CISS $3.49
- GLMD $2.22
- Average True Range (ATR)
- CISS 0.23
- GLMD 0.13
- MACD
- CISS -0.00
- GLMD 0.02
- Stochastic Oscillator
- CISS 28.72
- GLMD 67.80
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.